PIA
PBYI icon

Piedmont Investment Advisors’s Puma Biotechnology PBYI Stock Holding History

Piedmont Investment Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-506
Closed -$30K – 1921
2018
Q2 		$30K Buy
+506
New +$29.3K ﹤0.01% 1462

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Piedmont Investment Advisors's PBYI Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 506 shares — an estimated $30K sold.

Piedmont Investment Advisors first reported a position in PBYI in Q2 2018 and held it in 1 quarter. The position peaked at $30K in Q2 2018. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 506 Puma Biotechnology shares in Q3 2018, an estimated $30K.
  • Piedmont Investment Advisors first reported a position in Puma Biotechnology in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Puma Biotechnology position peaked at $30K in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.